Literature DB >> 2527549

Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.

E D Anderson1, A P Forrest, P A Levack, U Chetty, R A Hawkins.   

Abstract

Forty-three patients with large (greater than or equal to 4 cm) but operable carcinoma of the breast have been treated by endocrine manipulation before definitive local surgery. This has allowed the study of the relationship between response to therapy and pretreatment oestrogen receptor (ER) concentration, as measured by a dextran-coated charcoal adsorption method. Premenopausal patients (17) were treated by surgical (4) or medical (13) oophorectomy. Post-menopausal patients (26) received either tamoxifen (10) or an aromatase inhibitor (16). Response was assessed from statistical analysis of the changes in tumour size. On completion of 12 weeks of endocrine therapy, there was significant regression of tumour size in 18 of the 43 patients. All 18 patients had tumours with ER concentrations of greater than or equal to 20 fmol mg-1 cytosol protein. Conversely all patients except one progressing on treatment had tumours with ER concentrations of less than 20 fmol mg-1 cytosol protein. This relationship applied for both premenopausal and post-menopausal patients. The overall response rate of patients with tumours of ER concentration greater than or equal to 20 fmol mg-1 cytosol protein was 60%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527549      PMCID: PMC2247025          DOI: 10.1038/bjc.1989.256

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.

Authors:  A R Bianco; S De Placido; C Gallo; C Pagliarulo; A Marinelli; G Petrella; M D'Istria; G Delrio
Journal:  Lancet       Date:  1988-11-12       Impact factor: 79.321

2.  Long-term survival of women with breast cancer.

Authors:  D Brinkley; J L Haybittle
Journal:  Lancet       Date:  1984-05-19       Impact factor: 79.321

3.  Estrogen receptors in hormone-dependent breast cancers.

Authors:  E V Jensen
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

4.  Steroid receptors and response to endocrine ablations in women with metastatic cancer of the breast.

Authors:  T L Dao; T Nemoto
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

5.  Relation of tumor content of estrogen and progesterone receptors with response of patient to endocrine therapy.

Authors:  S C Brooks; D E Saunders; A Singhakowinta; V K Vaitkevicius
Journal:  Cancer       Date:  1980-12-15       Impact factor: 6.860

6.  Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle.

Authors:  R L Sutherland; M D Green; R E Hall; R R Reddel; I W Taylor
Journal:  Eur J Cancer Clin Oncol       Date:  1983-05

7.  Fine needle aspiration cytology, in relationships to clinical examination and mammography in the diagnosis of a solid breast mass.

Authors:  J M Dixon; T J Anderson; J Lamb; S J Nixon; A P Forrest
Journal:  Br J Surg       Date:  1984-08       Impact factor: 6.939

8.  Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.

Authors:  B Fisher; C Redmond; A Brown; E R Fisher; N Wolmark; D Bowman; D Plotkin; J Wolter; R Bornstein; S Legault-Poisson
Journal:  J Clin Oncol       Date:  1986-04       Impact factor: 44.544

9.  Oestrogen receptor concentration in primary breast cancer and axillary node metastases.

Authors:  R A Hawkins; R Black; R J Steele; J M Dixon; A P Forrest
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

10.  A human tumour model.

Authors:  A P Forrest; P A Levack; U Chetty; R A Hawkins; W R Miller; J F Smyth; T J Anderson
Journal:  Lancet       Date:  1986-10-11       Impact factor: 79.321

View more
  16 in total

Review 1.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

2.  Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.

Authors:  D A Cameron; E D Anderson; P Levack; R A Hawkins; T J Anderson; R C Leonard; A P Forrest; U Chetty
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 3.  Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

4.  Paracrine interaction in co-culture of hormone-dependent and independent breast cancer cells.

Authors:  V Cappelletti; C Ruedl; P Miodini; L Fioravanti; D Coradini; G Di Fronzo; R Silvestrini
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  The differing predictive values of oestrogen receptor assays for large breast cancers.

Authors:  D J Gaskell; R A Hawkins; A L Tesdale; K Sangster; U Chetty; A P Forrest
Journal:  Postgrad Med J       Date:  1992-11       Impact factor: 2.401

6.  PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer.

Authors:  A M Thompson; R A Elton; R A Hawkins; U Chetty; C M Steel
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

7.  Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer.

Authors:  A M Thompson; D J Kerr; C M Steel
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

8.  Primary systemic therapy for operable breast cancer.

Authors:  E D Anderson; A P Forrest; R A Hawkins; T J Anderson; R C Leonard; U Chetty
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

9.  Expression of transforming growth factor beta mRNA isoforms in human breast cancer.

Authors:  J MacCallum; J M Bartlett; A M Thompson; J C Keen; J M Dixon; W R Miller
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

10.  Does the oestrogen receptor concentration of a breast cancer change during systemic therapy?

Authors:  R A Hawkins; A L Tesdale; E D Anderson; P A Levack; U Chetty; A P Forrest
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.